A tiny gene mutation in human liver cells could one day influence how high or low a dose patients need of about half of the clinically used drugs on the market, new research suggests. Scientists have identified this mutation, and have shown that it alters the level of a protein in the liver responsible for processing between 45 percent and 60 percent of medications used to treat a wide range of conditions.